India, April 1 -- image credit- shutterstock

Pune-based Gennova Biopharmaceuticals, a subsidiary of Emcure Pharmaceuticals, is advancing the development of a pathbreaking self-amplifying mRNA (saRNA) vaccine against the deadly Nipah virus.

This critical initiative is supported by an expanded partnership with Norway-based Coalition for Epidemic Preparedness Innovations (CEPI), with funding of up to $13.38 million.

Gennova will also team up with US-basedHouston Methodist Research Institute (HMRI), also a CEPI partner, to use their cutting-edge AI technology to optimize the properties of proteins derived from the virus that could stimulate the immune system and serve as optimal vaccine targets for Gennova to investigate in the lab and in ...